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We have previously found in experimental studies
in mice that it is possible to achieve high levels of
active immunity against tumour specific
transplantation antigens of methylcholanthrene
induced syngeneic sarcomas by immunising animals
with tumour cells to which tuberculin has been
coupled (Vyarkarnam et al., 1984). When these cells
are used to immunise animals that have previously
been given BCG or that have been injected with
cloned helper T cells reacted against tuberculin, the
mice raise anti-tumour responses that are very
much stronger than those given against injections
of cells not bearing tuberculin; or than those given
against tuberculin-bearing cells by BCG negative
animals. This is an example of the technique called
"Heterogenisation" of tumour cells (Kobayashi,
1982). It was originally demonstrated by
Lindenmann & Klein (1967) that tumour cells
infected with influenza virus gave rise to an
enhanced anti-tumour response. Our own work has
demonstrated that this is a typical linked
recognition, hapten-carrier phenomenon and that it
is the helper T cell response to the tuberculin which
is involved in generating the enhanced anti-tumour
responses and that indeed the same clones of helper
T cells which will help B cells make antibodies to
the hapten NIP will also help mice raise T cells
response against tumour antigens when the mice are
immunised with tuberculin coupled tumour cells (Sia
et al., 1984).
Encouraged by the successful outcome of this
technique in mice we have attempted to use the
same system in a trial of active immunotherapy for
a human tumour. The tumour chosen was
squamous cell carcinoma of the lung since there is
reason to believe that this is indeed a chemically-
induced tumour and since the conventional
treatment for this tumour does not involve post-
operative therapeutic regimens that are strongly
immunosuppressive.
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Patients of either sex up to the age of 75 and
with a histologically proven diagnosis of bronchial
squamous carcinoma and suitable for resection with
curative intent were eligible for this study. Pre-
operative assessment included conventional chest X-
ray and tomography, but not computerised axial
tomography. Isotopic liver and bone, but not brain,
scans were also performed routinely. Following
appropriate surgery with curative intent (lobectomy
or pneumonectomy), detailed macroscopic and
histopathological examinations were made to
exclude incomplete excision at the bronchial stump
or microscopic tumour involvement of lymph nodes
at the excision stage.
Twenty-five patients thus deemed to have the
tumour completely excised were entered into the
study between 1979 and 1983. Of these, the first 9
were all treated according to the immunotherapy
schedule of the protocol. Subsequently 3 of the 9
were found on histological review not to be
squamous carcinoma in type (one oat cell; 2
adenocarcinoma) and these have been excluded
from the subsequent analysis. The second group of
16 patients were randomly allocated either to a
control group of surgery alone (n=9) or surgery
plus immunotherapy (n=7). All had confirmation
of the histological diagnosis of squamous cell
carcinoma at review. Follow up of patients after
completion of immunotherapy was at 3 monthly
intervals for the first 2 years, and 6 monthly
subsequently. Treatment of recurrence was at the
discretion of the physician by whatever method
seemed appropriate. Local ethical committee
approval of the protocol was obtained together
with informed patient consent.
The tumour was chopped finely with scissors and
washed repeatedly in Hanks BSS to remove as
much blood contamination as possible. The cells
were disaggregated with 0.5% trypsin in HBSS, in
two half hour incubations at 37°C with stirring (if
the tumour contained much necrotic material
100pgml-' DNAase was added to the
incubations). The trypsin was inactivated with
normal human serum to a final concentration of
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10%. The cell suspension was filtered through fine
stainless steel gauze filters to remove large pieces of
debris. The cells were then washed x 3 in HBSS,
and finally resuspended in Dulbecco modified
Eagle's medium containing 10% NHS, 100uml-1
Penicillin, 100,ugml-1 Streptomycin, 2 igml-1
Fungizone (Amphotericin B), (if the tumour
contained much necrotic material 200jugml-1
Gentamycin sulphate was also used) and incubated
overnight at 37°C to allow resynthesis of cell
membrane components.
The cells were harvested by centrifugation, their
viability assessed using fluorescein diacetate, and
resuspended in a small volume (5-10ml) of
Dulbecco Minimal Eagle's Medium (MEM)
containing 10% human serum and glycerol. A
small amount of the cell suspension was tested for
bacterial contamination by the clinical bacteriology
laboratory and the remainder frozen at -70°C in
aliquots of 107 cells. This procedure has been tested
and confirmation of bacteriologically sterile
specimens obtained.
When cells were to be used an aliquot was
thawed rapidly at 37°C and washed x 2 in Dulbecco
MEM to remove glycerol. These were then
irradiated to a dose of 100Gy to eliminate their
clonogenic potential. Sterile Con A-PPD (prepared
as described by Lachmann et al., 1981) was added
aseptically and coupling was allowed to occur for
30min at 37°C. The amount of Con A-PPD was
sufficient to give 106 molecules PPD/cell. The vial
was centrifuged, the supernatant was withdrawn,
and the cells were resuspended in sterile saline for
injection.
On first allocation to the immunotherapy group
the patients received 0.2ml Tice BCG i.d. at two
sites. Two weeks after surgery they were injected
with 5 x 107 autologous tumour cells, irradiated
with 100Gy and coupled with Con A-PPD. This
was followed two weekly by 5 x 107 uncoupled
irradiated autologous tumour cells. Six injections
were administered over a 12 week period.
The response to treatment was measured by the
time of survival from the date of entry to the study.
Survival rates were calculated by the actuarial
method and treatment groups compared using the
logrank test (Peto et al., 1977). The hazard ratio
was estimated by the method of Bernstein et al.
(1981).
The treatment was well tolerated. The BCG
injection produced an inflamed lesion of around 1-
2cm diameter in all the patients - most of whom
were presumably already PPD-sensitive. These
lesions all healed normally.
There were no local or systemic reactions to the
injections of the PPD-coupled tumour cells. The
only effect observed in a number of patients was a
slight "light-up" reaction seen as erythema at the
BCG site occurring the day after the injections,
showing that some PPD-related reaction was
occurring.
The survival curves for the patients treated in the
pilot study and for the control and treatment group
in the main study are shown in Figure 1. The
numbers of patients in each group are very small
and none of the differences are statistically
significant (e.g. treatment vs. control: x2 = 1.1 on
1 df, P=0.03).
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Figure 1 Survival curves for the three treatment
groups. (-) pilot; (--) treatment; (--) control.
When treatment and pilot groups were combined
and compared with the control the hazard-ratio
was estimated as 0.33 but the confidence interval
was very wide, from 0.06 to 1.72. A hazard-ratio of
less than one indicates benefit from the treatment.
If 3 year survival for the control group were 50%
than a hazard-ratio of 0.33 would represent an
increase to 80%.
Antibody was measured in 12 patients who had
between 1 and 6 separate bleeds each (36 tests in
all).
Mixed allogeneic lung tumour cells (from patients
not being immunised) were used as antigen. The
cells were washed twice in PBS/azide and 105 cells
were used as the test aliquot.
Sera from patients receiving immunotherapy were
heat inactivated for 30min at 56°C and absorbed
twice with 25% volume of human blood group AB
erythrocytes.
The test sera were tested at a single dilution of
1/10 and 100 l1 incubated with the tumour cells for
1 h at room temperature. After washing twice the
cells were incubated with 1251 sheep anti-human
Fab' for I h at room temperature, washed twice
and counted for 1251.
No significant uptake of radiolabel was found in
any sample.
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It was concluded that no antibody to a tumour
specific cell surface antigen reacting with allogeneic
cells had been found.
Although this study has involved only a small
number of patients and for this reason does not
reach adequate statistical levels of significance we
feel it is worth reporting at this stage for the
following reasons.
(1) It clearly demonstrates that the technique of
injecting PPD coupled, irradiated tumour cells into
autologous hosts is harmless and accompanied by
no complications.
(2) There is some suggestive evidence that the
treatment may have some beneficial effect and that
it will be worthwhile repeating the study with larger
numbers of patients and with an amended protocol.
No antibodies reactive with allogeneic squamous
lung tumour cells could be measured, suggesting
that such immunity as is achieved is likely to be cell
mediated.
(3) We would not repeat the study in exactly the
form in which it was first initiated. The reason for
this is that an important change in our ideas about
the nature of tumour specific transplantation
antigens has occurred since the study was initiated.
At that time it was believed that the individual
tumour specific transplantation antigens found on
methylcholanthrene-indluced sarcomas in mice were
a good model for what might be expected in human
tumours especially those that were also chemically
induced. The recent work of Lennox and his group
(1981) demonstrating that these individually specific
transplantation antigens are likely to be
recombinant retrovirus proteins suggests that they
are a poor model for human tumour
transplantation antigens since humans do not share
the relationship with retroviruses that is found in
mice and that makes the generation of such
recombinant antigens a plausible event. If, as seems
increasingly likely, the tumour associated antigens
on human tumours are differentiation antigens,
then the justification for immunising only with
autologous tumour cells largely disappears and
indeed a theoretical case might be made out for
believing that allogeneic cells might be a better
immunogen. The practical difficulties encountered
with the trial were due in part to the requirement of
using only autologous cells and this was
responsible, in no small part, for the low level of
recruitment.
A trial using pooled allogeneic cells will be much
easier to perform. Furthermore, immunisation with
allogeneic cells can be continued indefinitely with
periodic booster injections. A trial of this kind
using allogeneic tumour cells coupled with Con A-
PPD is being initiated.
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